期刊
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
卷 28, 期 1, 页码 59-69出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.beem.2013.11.005
关键词
Adiponectin; AdipoR1; AdipoR2; T-cadherin; cancer; signaling
资金
- National Institute of Health, National Cancer Center [P30 CA030199]
- National Health and Medical Research Council of Australia [ID1006200]
- Cancer Council of New South Wales [IG11-27]
- Robert W. Storr Bequest to the University of Sydney
- NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER
Obesity is linked to increased cancer risk. Pathological expansion of adipose tissue impacts adipocyte function and secretion of hormonal factors regulating tissue homeostasis and metabolism. Adiponectin is an adipocyte-secreted, circulating hormone with pleiotropic functions in lipid and glucose metabolism, and beneficial roles in cardiovascular functions and inflammation. In obesity, decreased Adiponectin plasma levels correlate with tumor development and progression. The association of Adiponectin with potential tumor-limiting functions has raised significant interest in exploring this adipokine as a target for cancer-diagnostic and therapeutic applications. Recent studies, however, also implicate Adiponectin in supporting malignancy. This review highlights the evidence that links Adiponectin signaling to either cancer-protective or cancer-supporting functions. In this context, we discuss Adiponectin interactions with its receptors and associated signaling pathways. Despite significant advances in understanding Adiponectin functions and signaling mechanisms, its role in cancer remains multifaceted and subject to controversy. (C) 2013 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据